Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “PLASMODIUM”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,729 records · Page 96Linked to original sources

A protective monoclonal antibody recognizes a variant-specific epitope in the precursor of the major merozoite surface antigen of the rodent malarial parasite Plasmodium yoelii.

The precursor of the major merozoite surface Ag (PMMSA) represents one of the principal molecules of the erythrocytic stages of malarial parasites. Previously we reported that mAb 302 recognizing the 230-kDa PMMSA of Plasmodium yoelii provided passive protection to mice challenged with this parasite. We now report that the protective capacity of mAb 302 is variant specific, affording protection against infection with only three of five P. yoelii lines. Immunoprecipitation analyses of their PMMSA revealed that the expression of the epitope recognized by mAb 302 also varied and correlated completely with the results of the passive protection studies. Although this specific determinant was not present on the merozoite Ag of all P. yoelii lines, the common expression of other B cell epitopes was noted by the demonstration of serologic cross-reactivity between these molecules. Furthermore, the relatedness of the genes encoding the PMMSA of several murine plasmodial strains and species was clearly shown in nucleic acid hybridization studies. Although strain-common and strain-variable epitopes have been observed in the PMMSA of the human parasite, Plasmodium falciparum, little is known concerning the variability of its biologically relevant epitopes. The current studies using the P. yoelii model system demonstrate that the epitope recognized by a protective mAb is strain variable. Because of the similarities between these antigens of P. falciparum and P. yoelii, this information may impact on the construction of an effective blood-stage malarial vaccine.

Animals↗

A protective monoclonal antibody recognizes an epitope in the carboxyl-terminal cysteine-rich domain in the precursor of the major merozoite surface antigen of the rodent malarial parasite, Plasmodium yoelii.

The 195-kDa major merozoite surface antigen of Plasmodium falciparum (Pf PMMSA) is a potential candidate for the development of a blood-stage malarial vaccine. We have focused on an analogous 230-kDa Ag of the rodent malarial parasite, Plasmodium yoelii, in an effort to study this protein in an experimental model system. Previously we reported the cloning and sequencing of a 2.1-kb portion of the gene encoding the carboxyl-terminal 77 kDa of the Py PMMSA. This region contained the B cell epitope recognized by mAb 302, a mAb shown to protect mice passively against P. yoelii challenge infection. To localize this B cell epitope, we have inserted various restriction fragments of the cloned Py PMMSA sequence into the bacterial expression vector pMG27NSTerm. Recombinant peptides of 74, 40, 34, 17, and 10 kDa have been produced which bear the epitope recognized by mAb 302. The results demonstrate that this B cell epitope is located within the most carboxyl-region of the Py PMMSA which contains a series of ten cysteine residues, also found in the PMMSA of P. falciparum. Further analysis showed that the reduction of disulfide bonds as well as the deletion of CYS-607 of the cloned sequence, resulted in the loss of the expression of this epitope. It is of interest that this epitope does not appear to be a dominant B cell determinant of the Py PMMSA molecule during infection. Inasmuch as this cysteine-rich domain of Py PMMSA displays considerable homology with that of Pf PMMSA, our data suggest that this region of the Pf PMMSA should be considered for inclusion in the development of a blood-stage vaccine.

Amino Acid Sequence↗

The causal prophylactic activity of the novel hydroxynaphthoquinone 566C80 against Plasmodium berghei infections in rats.

The influence of the novel hydroxynaphthoquinone 566C80 on exoerythrocytic development of Plasmodium berghei was examined in Brown Norway rats. The procedure employed was designed to identify residual activity of the drug against tissue merozoites emerging into the bloodstream and to distinguish this from any observed causal prophylactic activity against the liver stages. Single oral doses of 10 and 1 mg/kg of 566C80 administered 3 hours after sporozoite-inoculation were effective in preventing the appearance of a patent parasitaemia, while a dose of 0.1 mg/kg significantly reduced the severity of the ensuing blood infection. There was a pronounced residual effect of 566C80 against the blood forms at a dose of 10 mg/kg, a slight residual effect at a dose of 1 mg/kg, but no apparent residual effect at 0.1 mg/kg. At the time when EE merozoites would normally emerge into the bloodstream, an aliquot of blood was sub-inoculated into mice from sporozoite-infected, 566C80-treated rats. This procedure confirmed that 566C80 is active against the exoerythrocytic stages of Plasmodium berghei.

Animals↗

[In vivo study of chloroquine resistance of Plasmodium falciparum malaria in Mayotte].

According to the existence of Plasmodium falciparum chloroquine-resisting cases in Madagascar and, someone, in the Comoro Archipelago, a study using in vivo W.H.O. test was conducted in Mayotte Island. Between the end of 1985 and 1987, despite the great difficulties for ambulatory blood collection in a rural population, 24% of malaria cases had been followed up during 28 days, using a dose of 25 mg/Kg in 3 days. During 1986 and 1987, 5 cases showed positive serology of thin blood films. Either the possibility of reinfection cannot be excluded, these cases may be notified as R I and R II resistant type according to the W.H.O. standard test. In vitro W.H.O. test is necessary to confirm this fact but is not possible in local laboratory conditions. Thus, the surveillance of chemosensitivity of Plasmodium falciparum local strains is a priority. Nevertheless, chloroquine remains efficient for prophylactic (new travelers only) or curative purpose in the main cases.

Animals↗

[Comparative efficacy of alternative treatments in Plasmodium falciparum infections in Zaire].

The in vivo sensitivity of Plasmodium falciparum for chloroquine, quinine and pyrimethamine-sulfadoxine has been evaluated in 3 of 14 sentinel antimalarial drugs sensitivity surveillance centres between October 1986 and July 1987. Children of less than five years old were treated with chloroquine at 25 mg/kg dose administered during 3 days, or with 140 mg/kg quinine base administered in a daily dose of 20 mg/kg during 7 consecutive days, or with one standard dose of 1/2 a pyrimethamine-sulfadoxine tablet for children between 3 and 48 months old and 1 tablet for children between 49 and 59 months old, or the combination of 60 mg/kg quinine base at 20 mg/kg single dose during 3 consecutive days with the association pyrimethamine-sulfadoxine in single dose at the first day of treatment. A modified standard 7 days in vivo test of the World Health Organization was used 2, 3 and 7 days after the start of treatment. In one location an additional observation was made on day 14. The results, compared by location and by drug regimen, show a varying but relatively important reduction of the activity of chloroquine on the parasitological level. Quinine in maximal but single dose also shows reduction in activity, especially on day 14 in the Tshela centre. The pyrimethamine-sulfadoxine association shows a better activity. On the clinical level, e.g. temperature remission after treatment, all antimalarials still maintain their activity. As a result, and in view of its persisting high clinical activity, chloroquine at 25 mg/kg dose remains the drug of first choice for the treatment of uncomplicated Plasmodium falciparum infections.

Animals↗

[A handy medium for in vitro assessment of sensitivity of Plasmodium falciparum to chloroquine and mefloquine in the field].

The use of liquid RPMI 1640 medium (added NaHCO3 and serum) in sealed ampoule for in vitro assessment of sensitivity of Plasmodium falciparum to chloroquine and meflopuine in the field was very successful. On chloroquine plates with WHO supplied medium, 9 of 13 isolates were interpretable (successful rate 69.2%), the maturation rate from ring-forms to schizonts was 53.3%, the average number of nuclei per schizont 5.1. With lyophilized medium the successful rate was 100%, the maturation rate 65.9%, the average number of nuclei per schizont 7.4, while with medium in sealed ampoule, the corresponding figures were 92.3%, 65.1% and 7.3 respectively. On mefloquine plates with WHO supplied medium, 7 of 11 isolates were interpretable (63.6%). In control wells, 52.3% of schizonts matured, the number of nuclei per schizont was 5.1. With lyophilized medium the successful rate was 100%, the maturation rate 61.9%, the number of nuclei was 8.1, while those with liquid medium in sealed ampoule were 100%, 59.8% and 7.5 respectively. The results showed that the liquid medium in sealed ampoules stored within 56 days at 4 degrees C could still support the growth of Plasmodium falciparum, its supporting effect being better than that of WHO standard medium, but similar to lyophilized medium. The liquid medium in sealed ampoule had the advantages of easy carrying time-saving and more applicability under field conditions.

Animals↗

The antioxidants as protectors of host stress organ injury in mice infected with Plasmodium berghei.

A study has been made of counteracting the stress organ injury in Plasmodium infection by means of antioxidants on the premise that free radicals are responsible for causing the injury to stress organs. This was evidenced by drastically altered biochemical parameters in liver and spleen of the host in terms of elevated levels of lipid peroxides and xanthine oxidase (XO) activity, and a fall in superoxide dismutase activity coupled with other drastic biochemical changes. The cardinal factor responsible for the above was considered to be XO which engenders free radicals purportedly responsible for the stress organ (biochemical) injury. Results demonstrate a lowering of lipid peroxide levels, xanthine oxidase activity, liver weight and modulation of protein level in liver of the host (mouse) in Plasmodium infection when treated with catechin, glutathione and propylgallate.

Animals↗

[Plasmodium falciparum malaria attacks with low or negative parasitemia on returning from areas of endemic resistance to 4-aminoquinolines].

Twelve recent cases of Plasmodium falciparum malaria presented with unusual clinical and laboratory features. All patients had regularly been taking adequate doses of amino-4-quinolines as prophylaxis. In most cases the symptoms were mild as compared with those in a group of 20 control patients with typical malaria. More surprisingly, parasitaemia was either negative or very weakly positive (less than 1000 infested erythrocytes per mm3). All cases occurred in people returning from areas in which resistance of P. falciparum to these drugs is endemic. Diagnostic problems could be solved in most patients by new immunological techniques relying on the detection of parasitized erythrocytes and plasmodium antigens using a battery of monoclonal antibodies. A physiopathological model explaining why parasitaemia is negative in such cases is suggested.

Amodiaquine↗

[Stimulation of the chemiluminescence of human polymorphonuclear leukocytes in various stages of the intraerythrocyte development of Plasmodium falciparum].

The synchronized cultures of Plasmodium falciparum were used to stimulate in vitro the chemiluminescence of human polymorphonuclear leukocytes in the presence of immune serum. The schizonts were concentrated by Percoll gradient centrifugation method (density 1.085 and osmolarity 285 mOsmol), and placed in culture, treated 6 hours later by sorbitol. Under incubation at constant temperature and pressure, the rate of synchronization reached 85% for schizonts during 5 replicative cycles. Every asexual stages of Plasmodium falciparum were used separately to stimulate polymorphonuclear leukocytes: merozoites were the most effective, followed by schizonts, trophozoites, and lastly supernatants of cultures containing degradation products of parasites.

Animals↗

[Response of Plasmodium falciparum to quinine in a hospital environment in a chloroquine-resistant region. Bujumbura, Republic of Burundi].

Plasmodium falciparum's response to quinine (7.5 g of base in 5 days) was studied in vivo in 58 adult patients hospitalized in 1985--47% presented a pernicious malaria fever three deaths were registered during treatment, two of them attributed to late hospitalization, and the third patient was struck down by a sudden acute hepatitis. Three days after treatment started 89 of the patients did not present any asexual forms. At day 7, all patients responded favourably to the treatment. Parasitemia lowered very quickly whatever the route of administration had been. Quinine had no effect on production of gametocytes during the first four days. Clinical improvement is rapidly observed and the side effects of quinine disappeared when stopping the treatment. Despite the presence in the region of an important resistance of Plasmodium falciparum to chloroquine (80% specimens), one can conclude to a satisfying susceptibility of this parasite to quinine, provided posology and divided doses are respected.

Adolescent↗

A model for Plasmodium falciparum sporozoite challenge and very early therapy of parasitaemia for efficacy studies of sporozoite vaccines.

Plasmodium falciparum parasitaemias were induced in four non-immune volunteers by the bites of mosquitoes infected from cultured gametocytes. Radical cure was accomplished before three of the four volunteers developed clinical malaria. Despite very low peak levels of parasitaemia, the plasmodium was recultured from the blood of all volunteers. This volunteer model of early detection of parasitaemia and prompt treatment will contribute to the safe and practical efficacy testing of sporozoite vaccines, thus facilitating the selection of candidate vaccines for large scale definitive field trials.

Adult↗

[Intravector anti-Plasmodium activity of a pyrethrinoid: deltamethrin].

In vitro tests, deltamethrin reduced the parasitemic index of Plasmodium falciparum on human red blood corpuscles. In vivo tests, at sublethal doses, deltamethrin limited the development of the sporogonic cycle of Plasmodium yoelii yoelii in Anopheles stephensi. This novel type of antiplasmodic activity involve an intravectorial route and gives an explanation about surprising antimalaria effects observed several months after treatment.

Animals↗

Structure of the gene encoding the circumsporozoite protein of Plasmodium yoelii. A rodent model for examining antimalarial sporozoite vaccines.

The gene encoding the circumsporozoite protein (CSP) from the rodent malaria parasite, Plasmodium yoelii, has been cloned and the nucleotide sequence has been determined. The gene encodes a protein of 367 amino acids as deduced from the nucleotide sequence. This gene is structurally similar to other Plasmodium spp. CSP genes in that it contains putative hydrophobic signal and anchor sequences at the NH2 and COOH termini, respectively, two small regions (Regions I and II) that are conserved in all CSP genes analyzed to date, and a central region containing the immunodominant repeating peptide sequence. Unlike other CSP genes, however, the immunodominant repeat region of the gene is composed of two distinctly different types of tandem repeats. One repeating unit is six amino acids (Gln-Gly-Pro-Gly-Ala-Pro) in length while the other is only four (Gln-Gln-Pro-Pro) residues long. A synthetic peptide, Gln-Gly-Pro-Gly-Ala-Pro X 3, strongly inhibits the binding of anti-CSP monoclonal antibody to sporozoite antigens while another peptide, Gln-Gln-Pro-Pro X 4, weakly inhibits the binding of this same antibody to sporozoite antigens. This work should allow the construction of a mouse model system to parallel human vaccine trials.

Amino Acid Sequence↗

Experimental modifications of the circadian rythm of Plasmodium vinckei petteri following cryopreservation; probable resistance of the merozoïte to thawing.

Plasmodium vinckei petteri, in white mice, is a particularly useful strain for studies on the circadian rythm of Plasmodium. An experimental model was set up: it showed that the rythm of asexual schizogony in the blood varies with the time and the mode of inoculation (cryopreserved blood or syringe passage). When frozen blood is injected, the time of schizogony depends on the time of injection; on the contrary, when the passage is by syringe from mouse to mouse, the rythm of schizogony is the same in the donor and the receptor mouse, regardless of the time of injection. The only possible explanation is that all intracellular parasites are destroyed by the thawing of blood and the free merozoïte is the only resistant stage.

Animals↗

Immunoelectron microscopy of Schüffner's dots in Plasmodium vivax-infected human erythrocytes.

Plasmodium vivax induces morphologic alterations in infected host erythrocytes that are visible by light microscopy in Romanovsky-stained blood smears as multiple brick-red dots. These morphologic changes, referred to as Schüffner's dots, are important in the identification of this species of malarial parasite and have been associated by electron microscopy with caveolavesicle complexes along the erythrocyte plasmalemma. We have produced a monoclonal antibody (MAb A 20) that identifies an antigen in Plasmodium vivax-infected erythrocytes that is associated with the caveola-vesicle complexes of the parasitized host cell. This monoclonal antibody reacts with air-dried P vivax-infected erythrocytes to produce a pattern by the indirect immunofluorescence test (IFT) that is evocative of Schüffner's dots. Immunoelectron microscopy of P vivax-infected human erythrocytes using MAb A 20 confirmed the location of this antigen within vesicles of caveola-vesicle complexes. On Western blots MAb A 20 recognized four polypeptides of 54, 64, 72, and 86 kd. MAb A 20 reacted by IFT with 90% of Sri Lankan isolates and with a Brazilian P vivax isolate, which indicates that the epitope identified by this monoclonal is conserved.

Animals↗

Effect of trans(E)-clopenthixol on Plasmodium berghei in vivo.

Previous in vitro studies have shown suppression of the growth of Plasmodium falciparum by the neuroleptic agents chlorpromazine and zuclopenthixol (formerly known as cis(Z)-clopenthixol) as well as by the neuroleptic inactive steroisomer trans(E)-clopenthixol. These compounds are chemically related to riboflavin and may act as inhibitors of riboflavin metabolism. As trans(E)-clopenthixol has been found active against chloroquine-resistant strains of P. falciparum in vitro and has been approved for human use, though inactive as a neuroleptic, this drug was selected for the present in vivo study. The dosage of trans(E)-clopenthixol was optimized through a pharmacokinetic study, and the suppression of the growth of Plasmodium berghei in vivo was tested in mice, with chloroquine acting as the positive and saline as the negative control. Trans(E)-clopenthixol did not inhibit the growth of P. berghei, whereas chloroquine almost eradicated the infection. The use of in vitro screening for anti-malarial activity in drugs approved for human use for other indications is discussed in the light of the results. It is concluded that the selection of drugs for further studies in vivo cannot solely be based on positive results in vitro.

Animals↗

[Current aspects of imported drug-resistant Plasmodium falciparum].

24 cases of Plasmodium falciparum malaria in a group of 73 non-immune subjects coming mostly from central Africa have been tested in vitro for chloroquine sensitivity: 5 are sensitive, 19 are resistant among whom one is also quinine-resistant. The comparison of the major clinical and biological features in the two groups by methods of statistical calculation shows that the parasitological diagnosis is retarded and that hemolysis is more frequent in the strains of Plasmodium falciparum resistant to chloroquine. Thrombopenia is more frequent with chemosensitives strains. In any case, the delay between the first symptoms and the parasitological diagnosis is increased with an average of 17 days in comparison to what was observed in the 1970's. Under the influence of several complex factors including human ones, the clinical aspects are changed in comparison to forms usually observed. In this context of an extension of the emergence of the chemoresistance and in the aim of efficiency, only the quinine I.V., with an average dose of 16.5 mg/kg per day of quinine-base, has been chosen as a curative treatment during 5 days allowing a rapid recovery without after-effects for all the cases.

Adult↗